AN INTRODUCTION TO NIRSEVIMAB

Ivana Kalanović Dylag, Andrew Dylag
{"title":"AN INTRODUCTION TO NIRSEVIMAB","authors":"Ivana Kalanović Dylag, Andrew Dylag","doi":"10.46793/pp240220001k","DOIUrl":null,"url":null,"abstract":"Respiratory syncytial virus (RSV) is a dominating respiratory infection worldwide.  It is responsible for infecting millions of children worldwide each winter through highly contagious droplets and secretions. Over 2.1 million of these children require some form of medical attention during illness.  Due to this high disease burden, the development of new agents to prevent or reduce the spread of RSV has been a top priority.  Recently, nirsevimab, a new monoclonal antibody was introduced for the 2023-2024 winter season that holds promise for limiting the spread, morbidity, and mortality associated with RSV.","PeriodicalId":517496,"journal":{"name":"Preventive Paediatrics","volume":" 30","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Preventive Paediatrics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46793/pp240220001k","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Respiratory syncytial virus (RSV) is a dominating respiratory infection worldwide.  It is responsible for infecting millions of children worldwide each winter through highly contagious droplets and secretions. Over 2.1 million of these children require some form of medical attention during illness.  Due to this high disease burden, the development of new agents to prevent or reduce the spread of RSV has been a top priority.  Recently, nirsevimab, a new monoclonal antibody was introduced for the 2023-2024 winter season that holds promise for limiting the spread, morbidity, and mortality associated with RSV.
nirsevimab 简介
呼吸道合胞病毒(RSV)是全球主要的呼吸道传染病。 每年冬季,它都会通过传染性极强的飞沫和分泌物感染全球数百万儿童。其中 210 多万儿童在患病期间需要接受某种形式的医疗护理。 由于疾病负担沉重,开发预防或减少 RSV 传播的新制剂一直是重中之重。 最近,一种新型单克隆抗体 nirsevimab 于 2023-2024 年冬季上市,有望限制 RSV 的传播、发病率和死亡率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信